An initial trial suggests that a new drug, originally developed for use with cancer patients, could improve the survival of patients with acute respiratory distress syndrome (ARDS). The patients in ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window HONOLULU -- As ...

New study of 645 ARDS survivors has identified subgroups of ARDS survivors who suffer what's been called post-intensive care syndrome, a collection of symptoms that can linger for years. Patients who ...

Acute respiratory distress syndrome (ARDS) is characterized by increased pulmonary inflammation and endothelial barrier permeability. Omentin has been shown to benefit obesity-related systemic ...

Inhaled sedation with sevoflurane in patients with moderate to severe acute respiratory distress syndrome (ARDS) resulted in fewer ventilator-free days at 28 days and lower 90-day survival than ...

Trimethoprim-sulfamethoxazole (TMP-SMX) treatment may be linked to the onset of severe acute respiratory distress syndrome (ARDS) in adolescents, according to a recent case series published online May ...

On April 8, 2020, MediciNova, Inc. (NASDAQ:MNOV) announced that a clinical trial of MN-166 (ibudilast) will be initiated in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 ...

The SARS-CoV-2 pandemic has inspired new interest in understanding the fundamental pathology of acute respiratory distress syndrome (ARDS), which has been associated with severe coronavirus disease ...